{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:33:00Z","timestamp":1767677580313,"version":"3.48.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460211"],"award-info":[{"award-number":["82460211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]},{"name":"Guizhou Science and Technology Cooperation support","award":["[2023] general 265"],"award-info":[{"award-number":["[2023] general 265"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01978-4","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:54:37Z","timestamp":1765425277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dysregulation of the ubiquitin-proteasome system in von Hippel-Lindau syndrome: molecular insights and clinical perspectives"],"prefix":"10.1007","volume":"26","author":[{"given":"Yege","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"1978_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020362","author":"P Hudler","year":"2022","unstructured":"Hudler P, Urbancic M.\u00a0The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022;13:362.","journal-title":"Genes"},{"key":"1978_CR2","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/cncr.23645","volume":"113","author":"PE Clark","year":"2008","unstructured":"Clark PE, Cookson MS. The von Hippel-Lindau gene: turning discovery into therapy. Cancer. 2008;113:1768\u201378.","journal-title":"Cancer"},{"key":"1978_CR3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson","year":"1971","unstructured":"Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1978_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092313","author":"I de Rojas-P","year":"2021","unstructured":"de Rojas-P I, Albi\u00f1ana V, Taranets L, et al.\u00a0The Endothelial Landscape and Its Role in Von Hippel-Lindau Disease. Cells. 2021;10:2313.","journal-title":"Cells"},{"key":"1978_CR5","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000002555","volume":"39","author":"ME Aronow","year":"2019","unstructured":"Aronow ME, Wiley HE, Gaudric A, et al. VON HIPPEL-LINDAU DISEASE: update on pathogenesis and systemic aspects. Retina. 2019;39:2243\u201353.","journal-title":"Retina"},{"key":"1978_CR6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/neuonc\/nov313","volume":"18","author":"A Feletti","year":"2016","unstructured":"Feletti A, Anglani M, Scarpa B, et al. Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro Oncol. 2016;18:1011\u201320.","journal-title":"Neuro Oncol"},{"key":"1978_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clgc.2022.12.008","volume":"21","author":"E Jonasch","year":"2023","unstructured":"Jonasch E, Song Y, Freimark J, et al. Epidemiology and economic burden of von Hippel-Lindau Disease-associated renal cell carcinoma in the United States. Clin Genitourin Cancer. 2023;21:238\u201347.","journal-title":"Clin Genitourin Cancer"},{"key":"1978_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13023-024-03060-w","volume":"19","author":"E Jonasch","year":"2024","unstructured":"Jonasch E, Song Y, Freimark J, et al. Epidemiology and economic burden of von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the united States. Orphanet J Rare Dis. 2024;19:73.","journal-title":"Orphanet J Rare Dis"},{"key":"1978_CR9","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.2147\/OTT.S190753","volume":"13","author":"S Gl\u00e4sker","year":"2020","unstructured":"Gl\u00e4sker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO. Von Hippel-Lindau disease: current challenges and future prospects. Onco Targets Ther. 2020;13:5669\u201390.","journal-title":"Onco Targets Ther"},{"key":"1978_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2009.01281.x","volume":"77","author":"MLM Poulsen","year":"2010","unstructured":"Poulsen MLM, Budtz-J\u00f8rgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (vHL). Clin Genet. 2010;77:49\u201359.","journal-title":"Clin Genet"},{"key":"1978_CR11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","volume":"4","author":"N Varshney","year":"2017","unstructured":"Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of von Hippel-Lindau syndrome. J Kidney Cancer VHL. 2017;4:20\u20139.","journal-title":"J Kidney Cancer VHL"},{"key":"1978_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.15586\/jkcvhl.2015.41","volume":"2","author":"K Ashouri","year":"2015","unstructured":"Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE. Implications of von Hippel-Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL. 2015;2:163\u201373.","journal-title":"J Kidney Cancer VHL"},{"key":"1978_CR13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0300-2977(01)00165-6","volume":"59","author":"FJ Hes","year":"2001","unstructured":"Hes FJ, van der Luijt RB, Lips CJ. Clinical management of Von Hippel-Lindau (VHL) disease. Neth J Med. 2001;59:225\u201334.","journal-title":"Neth J Med"},{"key":"1978_CR14","unstructured":"Binderup MLM, Bisgaard ML, Harbud V et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J. 2013;60:B4763."},{"key":"1978_CR15","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/cncr.34896","volume":"129","author":"AB Daniels","year":"2023","unstructured":"Daniels AB, Tirosh A, Huntoon K, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023;129:2927\u201340.","journal-title":"Cancer"},{"key":"1978_CR16","first-page":"521","volume":"31","author":"M Nordstrom-O\u2019Brien","year":"2010","unstructured":"Nordstrom-O\u2019Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31:521\u201337.","journal-title":"Hum Mutat"},{"key":"1978_CR17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-0036-1579757","volume":"5","author":"JJ Findeis-Hosey","year":"2016","unstructured":"Findeis-Hosey JJ, McMahon KQ, Findeis SK. Von Hippel-Lindau disease. J Pediatr Genet. 2016;5:116\u201323.","journal-title":"J Pediatr Genet"},{"key":"1978_CR18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/gim.2017.261","volume":"20","author":"S Liu","year":"2018","unstructured":"Liu S, Wang J, Peng S, et al. Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-\u03b1 binding site in VHL protein. Genet Med. 2018;20:1266\u201373.","journal-title":"Genet Med"},{"key":"1978_CR19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5:66\u201375.","journal-title":"Hum Mutat"},{"key":"1978_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fonc.2020.00139","volume":"10","author":"SDF Boratto","year":"2020","unstructured":"Boratto SDF, Cardoso PAS, Priolli DG, et al. Von Hippel-Lindau syndrome: genetic study of case with a rare pathogenic variant with optic nerve Hemangioblastoma, a rare phenotypic expression. Front Oncol. 2020;10:139.","journal-title":"Front Oncol"},{"key":"1978_CR21","doi-asserted-by":"crossref","first-page":"38456","DOI":"10.18632\/oncotarget.16594","volume":"8","author":"S Peng","year":"2017","unstructured":"Peng S, Shepard MJ, Wang J, et al. Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients. Oncotarget. 2017;8:38456\u201365.","journal-title":"Oncotarget"},{"key":"1978_CR22","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/MCB.22.6.1947-1960.2002","volume":"22","author":"WJ Hansen","year":"2002","unstructured":"Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol. 2002;22:1947\u201360.","journal-title":"Mol Cell Biol"},{"key":"1978_CR23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13816810.2022.2138455","volume":"44","author":"M Naseripour","year":"2023","unstructured":"Naseripour M, Azimi F, Talebi S, et al. Investigation of germline VHL variants in Iranian patients with retinal capillary hemangioblastoma and genotype-phenotype analysis. Ophthalmic Genet. 2023;44:211\u20137.","journal-title":"Ophthalmic Genet"},{"key":"1978_CR24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41581-019-0148-1","volume":"15","author":"C Meyer-Schwesinger","year":"2019","unstructured":"Meyer-Schwesinger C. The ubiquitin-proteasome system in kidney physiology and disease. Nat Rev Nephrol. 2019;15:393\u2013411.","journal-title":"Nat Rev Nephrol"},{"key":"1978_CR25","doi-asserted-by":"crossref","unstructured":"Tokheim C, Wang X, Timms RT et al. Systematic characterization of mutations altering protein degradation in human cancers. Mol Cell. 2021;81:1292-308.e11.","DOI":"10.1016\/j.molcel.2021.01.020"},{"key":"1978_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s43556-021-00043-2","volume":"2","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhao J, Chen D, Wang Y. E3 ubiquitin ligases: styles, structures and functions. Mol Biomed. 2021;2:23.","journal-title":"Mol Biomed"},{"key":"1978_CR27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1593\/neo.06520","volume":"8","author":"RI Sufan","year":"2006","unstructured":"Sufan RI, Ohh M. Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex. Neoplasia. 2006;8:956\u201363.","journal-title":"Neoplasia"},{"key":"1978_CR28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1097-2765(00)80233-6","volume":"4","author":"DE Feldman","year":"1999","unstructured":"Feldman DE, Thulasiraman V, Ferreyra RG, Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin tric. Mol Cell. 1999;4:1051\u201361.","journal-title":"Mol Cell"},{"key":"1978_CR29","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1097-2765(03)00423-4","volume":"12","author":"DE Feldman","year":"2003","unstructured":"Feldman DE, Spiess C, Howard DE, Frydman J. Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. Mol Cell. 2003;12:1213\u201324.","journal-title":"Mol Cell"},{"key":"1978_CR30","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1128\/MCB.23.9.3141-3151.2003","volume":"23","author":"MW Melville","year":"2003","unstructured":"Melville MW, McClellan AJ, Meyer AS, Darveau A, Frydman J. The Hsp70 and TRiC\/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol Cell Biol. 2003;23:3141\u201351.","journal-title":"Mol Cell Biol"},{"key":"1978_CR31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2005.03.024","volume":"121","author":"AJ McClellan","year":"2005","unstructured":"McClellan AJ, Scott MD, Frydman J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell. 2005;121:739\u201348.","journal-title":"Cell"},{"key":"1978_CR32","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-22-3651","volume":"29","author":"P Chittiboina","year":"2023","unstructured":"Chittiboina P, Mandal D, Bugarini A, et al. Proteostasis modulation in germline missense von Hippel Lindau disease. Clin Cancer Res. 2023;29:2199\u2013209.","journal-title":"Clin Cancer Res"},{"key":"1978_CR33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/jmedgenet-2019-106336","volume":"57","author":"H Xie","year":"2020","unstructured":"Xie H, Ma K, Zhang J, et al. Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. J Med Genet. 2020;57:744\u201351.","journal-title":"J Med Genet"},{"key":"1978_CR34","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/hmg\/ddac066","volume":"31","author":"A Andreou","year":"2022","unstructured":"Andreou A, Yngvadottir B, Bassaganyas L, et al. Elongin C (ELOC\/TCEB1)-associated von Hippel-Lindau disease. Hum Mol Genet. 2022;31:2728\u201337.","journal-title":"Hum Mol Genet"},{"key":"1978_CR35","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45:860\u20137.","journal-title":"Nat Genet"},{"key":"1978_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100194","volume":"36","author":"AA Batavia","year":"2023","unstructured":"Batavia AA, Rutishauser D, Sobottka B, Schraml P, Beerenwinkel N, Moch H. Biallelic ELOC-inactivated renal cell carcinoma: molecular features supporting classification as a distinct entity. Mod Pathol. 2023;36:100194.","journal-title":"Mod Pathol"},{"key":"1978_CR37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.molcel.2007.01.001","volume":"25","author":"YV Liu","year":"2007","unstructured":"Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell. 2007;25:207\u201317.","journal-title":"Mol Cell"},{"key":"1978_CR38","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1073\/pnas.97.15.8507","volume":"97","author":"AR Schoenfeld","year":"2000","unstructured":"Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A. 2000;97:8507\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1978_CR39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-981-15-1025-0_11","volume":"1217","author":"X Liu","year":"2020","unstructured":"Liu X, Zurlo G, Zhang Q. The roles of Cullin-2 E3 ubiquitin ligase complex in cancer. Adv Exp Med Biol. 2020;1217:173\u201386.","journal-title":"Adv Exp Med Biol"},{"key":"1978_CR40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-3-319-46503-6_12","volume":"83","author":"HC Nguyen","year":"2017","unstructured":"Nguyen HC, Wang W, Xiong Y. Cullin-RING E3 ubiquitin ligases: bridges to destruction. Subcell Biochem. 2017;83:323\u201347.","journal-title":"Subcell Biochem"},{"key":"1978_CR41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.str.2014.12.014","volume":"23","author":"HC Nguyen","year":"2015","unstructured":"Nguyen HC, Yang H, Fribourgh JL, Wolfe LS, Xiong Y. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. Structure. 2015;23:441\u20139.","journal-title":"Structure"},{"key":"1978_CR42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nm1440","volume":"12","author":"C Jung","year":"2006","unstructured":"Jung C, Hwang K, Yoo J, et al. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med. 2006;12:809\u201316.","journal-title":"Nat Med"},{"key":"1978_CR43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1186\/s12885-015-1786-8","volume":"15","author":"K Park","year":"2015","unstructured":"Park K, Kim JH, Shin HW, et al. E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis. BMC Cancer. 2015;15:800.","journal-title":"BMC Cancer"},{"key":"1978_CR44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43:1144\u201361.","journal-title":"Arch Pharm Res"},{"key":"1978_CR45","doi-asserted-by":"crossref","first-page":"C1651","DOI":"10.1152\/ajpcell.00553.2024","volume":"327","author":"WX Du","year":"2024","unstructured":"Du WX, Goodman CA, Gregorevic P. Deubiquitinases in skeletal muscle-the underappreciated side of the ubiquitination coin. Am J Physiol Cell Physiol. 2024;327:C1651-C1651C1665.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1978_CR46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.embor.7400377","volume":"6","author":"Z Li","year":"2005","unstructured":"Li Z, Wang D, Messing EM, Wu G. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 2005;6:373\u20138.","journal-title":"EMBO Rep"},{"issue":"Suppl 1","key":"1978_CR47","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2091-9-S1-S3","volume":"9","author":"S Singhal","year":"2008","unstructured":"Singhal S, Taylor MC, Baker RT. Deubiquitylating enzymes and disease. BMC Biochem. 2008;9(Suppl 1):S3.","journal-title":"BMC Biochem"},{"key":"1978_CR48","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41418-023-01228-8","volume":"30","author":"M Mu","year":"2023","unstructured":"Mu M, Zhang Q, Li J, et al. USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A. Cell Death Differ. 2023;30:2393\u2013407.","journal-title":"Cell Death Differ"},{"key":"1978_CR49","doi-asserted-by":"crossref","first-page":"60519","DOI":"10.18632\/oncotarget.11139","volume":"7","author":"C Zhang","year":"2016","unstructured":"Zhang C, Peng Z, Zhu M, et al. USP9X destabilizes pVHL and promotes cell proliferation. Oncotarget. 2016;7:60519\u201334.","journal-title":"Oncotarget"},{"key":"1978_CR50","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4161\/cc.3.11.1207","volume":"3","author":"K Nakayama","year":"2004","unstructured":"Nakayama K, Ronai Z. Siah: new players in the cellular response to hypoxia. Cell Cycle. 2004;3:1345\u20137.","journal-title":"Cell Cycle"},{"key":"1978_CR51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41419-021-04135-3","volume":"13","author":"K Guo","year":"2022","unstructured":"Guo K, Wei Y, Wang Z, et al. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma. Cell Death Dis. 2022;13:97.","journal-title":"Cell Death Dis"},{"key":"1978_CR52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13238-018-0586-8","volume":"10","author":"D Aki","year":"2019","unstructured":"Aki D, Li Q, Li H, Liu Y, Lee JH. Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and itch. Protein Cell. 2019;10:395\u2013404.","journal-title":"Protein Cell"},{"key":"1978_CR53","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/j.febslet.2014.02.026","volume":"588","author":"CM Robinson","year":"2014","unstructured":"Robinson CM, Ohh M. The multifaceted von Hippel-Lindau tumour suppressor protein. FEBS Lett. 2014;588:2704\u201311.","journal-title":"FEBS Lett"},{"key":"1978_CR54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12881-016-0306-2","volume":"17","author":"J Lee","year":"2016","unstructured":"Lee J, Lee J, Lee KE, et al. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-\u03b1 binding site missense mutations elevate age-specific risk for CNS hemangioblastoma. BMC Med Genet. 2016;17:48.","journal-title":"BMC Med Genet"},{"key":"1978_CR55","volume":"19","author":"S Hwang","year":"2024","unstructured":"Hwang S, Kang SW, Kim J, Kim SJ. Genotype-phenotype correlation of ocular von Hippel-Lindau disease in Koreans. PLoS One. 2024;19:e0311665.","journal-title":"PLoS One"},{"key":"1978_CR56","doi-asserted-by":"crossref","first-page":"e3801","DOI":"10.1371\/journal.pone.0003801","volume":"3","author":"KE Hacker","year":"2008","unstructured":"Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS One. 2008;3:e3801.","journal-title":"PLoS One"},{"key":"1978_CR57","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval RR, Lau KW, Tran MGB, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25:5675\u201386.","journal-title":"Mol Cell Biol"},{"key":"1978_CR58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","volume":"1","author":"C Shen","year":"2011","unstructured":"Shen C, Beroukhim R, Schumacher SE, et al. Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene. Cancer Discov. 2011;1:222\u201335.","journal-title":"Cancer Discov"},{"key":"1978_CR59","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12094-012-0857-4","volume":"14","author":"VM Villaamil","year":"2012","unstructured":"Villaamil VM, Gallego GA, Ca\u00ednzos IS, Valladares-Ayerbes M, Aparicio LMA. Searching for Hif1-\u03b1 interacting proteins in renal cell carcinoma. Clin Transl Oncol. 2012;14:698\u2013708.","journal-title":"Clin Transl Oncol"},{"key":"1978_CR60","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00109-014-1180-z","volume":"92","author":"LJ Gudas","year":"2014","unstructured":"Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM. The role of HIF1\u03b1 in renal cell carcinoma tumorigenesis. J Mol Med (Berl). 2014;92:825\u201336.","journal-title":"J Mol Med (Berl)"},{"key":"1978_CR61","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/onc.2011.305","volume":"31","author":"J Xu","year":"2012","unstructured":"Xu J, Wang B, Xu Y, et al. Epigenetic regulation of HIF-1\u03b1 in renal cancer cells involves HIF-1\u03b1\/2\u03b1 binding to a reverse hypoxia-response element. Oncogene. 2012;31:1065\u201372.","journal-title":"Oncogene"},{"key":"1978_CR62","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","volume":"11","author":"R Hoefflin","year":"2020","unstructured":"Hoefflin R, Harlander S, Sch\u00e4fer S, et al. HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. 2020;11:4111.","journal-title":"Nat Commun"},{"key":"1978_CR63","doi-asserted-by":"crossref","first-page":"11032","DOI":"10.1074\/jbc.M208681200","volume":"278","author":"MA Maynard","year":"2003","unstructured":"Maynard MA, Qi H, Chung J, et al. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem. 2003;278:11032\u201340.","journal-title":"J Biol Chem"},{"key":"1978_CR64","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.4161\/cc.6.22.4947","volume":"6","author":"MA Maynard","year":"2007","unstructured":"Maynard MA, Evans AJ, Shi W, Kim WY, Liu F, Ohh M. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle. 2007;6:2810\u20136.","journal-title":"Cell Cycle"},{"key":"1978_CR65","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.1347","volume":"263","author":"H Okuda","year":"1999","unstructured":"Okuda H, Hirai S, Takaki Y, et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun. 1999;263:491\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1978_CR66","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.1011777108","volume":"108","author":"OV Razorenova","year":"2011","unstructured":"Razorenova OV, Finger EC, Colavitti R, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A. 2011;108:1931\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1978_CR67","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2012.00035","volume":"2","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Yang H. The roles of VHL-dependent ubiquitination in signaling and cancer. Front Oncol. 2012;2:35.","journal-title":"Front Oncol"},{"key":"1978_CR68","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1158\/1078-0432.CCR-09-3416","volume":"16","author":"Y Yi","year":"2010","unstructured":"Yi Y, Mikhaylova O, Mamedova A, et al. Von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas. Clin Cancer Res. 2010;16:5142\u201352.","journal-title":"Clin Cancer Res"},{"key":"1978_CR69","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1093\/emboj\/cdg410","volume":"22","author":"X Na","year":"2003","unstructured":"Na X, Duan HO, Messing EM, et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J. 2003;22:4249\u201359.","journal-title":"EMBO J"},{"key":"1978_CR70","volume":"300","author":"D Yang","year":"2024","unstructured":"Yang D, Li Q, Lu P, et al. FOXA2 activates HIF2\u03b1 expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma. J Biol Chem. 2024;300:105535.","journal-title":"J Biol Chem"},{"key":"1978_CR71","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/MCB.00067-16","volume":"36","author":"F Okumura","year":"2016","unstructured":"Okumura F, Uematsu K, Byrne SD, et al. Parallel regulation of von Hippel-Lindau disease by pVHL-mediated degradation of B-Myb and hypoxia-inducible factor \u03b1. Mol Cell Biol. 2016;36:1803\u201317.","journal-title":"Mol Cell Biol"},{"key":"1978_CR72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yexmp.2018.11.007","volume":"107","author":"G Du","year":"2019","unstructured":"Du G, Qiu Y, Wang W, et al. Knockdown on aPKC-\u03b9 inhibits epithelial-mesenchymal transition, migration and invasion of colorectal cancer cells through Rac1-JNK pathway. Exp Mol Pathol. 2019;107:57\u201367.","journal-title":"Exp Mol Pathol"},{"key":"1978_CR73","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14427.1","author":"Y Hong","year":"2018","unstructured":"Hong Y.\u00a0aPKC: the Kinase that Phosphorylates Cell Polarity. F1000Res. 2018;7:F1000 Faculty Rev-903 [pii].","journal-title":"F1000Res"},{"key":"1978_CR74","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cell.2020.02.009","volume":"180","author":"AT Vidakovi\u0107","year":"2020","unstructured":"Vidakovi\u0107 AT, Mitter R, Kelly GP, et al. Regulation of the RNAPII pool is integral to the DNA damage response. Cell. 2020;180:1245\u2013e6121.","journal-title":"Cell"},{"key":"1978_CR75","volume":"36","author":"L Ma","year":"2022","unstructured":"Ma L, Wang L, Gao M, et al. Rtr1 is required for Rpb1-Rpb2 assembly of RNAPII and prevents their cytoplasmic clump formation. FASEB J. 2022;36:e22585.","journal-title":"FASEB J"},{"key":"1978_CR76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.31083\/j.fbl2906225","volume":"29","author":"J Zhu","year":"2024","unstructured":"Zhu J, Wei Y, Deng F, Zhou Y, Yang Z, Ma Y. The role of FOXA1 in human normal development and its functions in sex hormone-related cancers. Front Biosci (Landmark Ed). 2024;29:225.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1978_CR77","doi-asserted-by":"crossref","first-page":"e2478","DOI":"10.1371\/journal.pone.0002478","volume":"3","author":"KV Tarasov","year":"2008","unstructured":"Tarasov KV, Tarasova YS, Tam WL, et al. B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS One. 2008;3:e2478.","journal-title":"PLoS One"},{"key":"1978_CR78","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.jid.2023.02.043","volume":"143","author":"Z Yue","year":"2023","unstructured":"Yue Z, Lin J, Lu X, et al. Keratin 17 impacts global gene expression and controls G2\/M cell cycle transition in ionizing Radiation-Induced skin damage. J Invest Dermatol. 2023;143:2436\u2013e4613.","journal-title":"J Invest Dermatol"},{"key":"1978_CR79","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1593\/neo.121896","volume":"15","author":"L Arias-Gonz\u00e1lez","year":"2013","unstructured":"Arias-Gonz\u00e1lez L, Moreno-Gimeno I, Campo AR, et al. ERK5\/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia. 2013;15:649\u201359.","journal-title":"Neoplasia"},{"key":"1978_CR80","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1128\/MCB.00630-15","volume":"35","author":"M Radu","year":"2015","unstructured":"Radu M, Lyle K, Hoeflich KP, Villamar-Cruz O, Koeppen H, Chernoff J. P21-activated kinase 2 regulates endothelial development and function through the Bmk1\/Erk5 pathway. Mol Cell Biol. 2015;35:3990\u20134005.","journal-title":"Mol Cell Biol"},{"key":"1978_CR81","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2217\/pgs.13.184","volume":"14","author":"F Dias","year":"2013","unstructured":"Dias F, Teixeira AL, Santos JI, et al. Renal cell carcinoma development and mirnas: a possible link to the EGFR pathway. Pharmacogenomics. 2013;14:1793\u2013803.","journal-title":"Pharmacogenomics"},{"key":"1978_CR82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150517","author":"D Yan","year":"2022","unstructured":"Yan D, Huelse JM, Kireev D, et al.\u00a0MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. J Clin Invest. 2022;132:e150517.","journal-title":"J Clin Invest"},{"key":"1978_CR83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng1254","volume":"35","author":"PG Corn","year":"2003","unstructured":"Corn PG, McDonald ER 3rd, Herman JG, E-D WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet. 2003;35:229\u201337.","journal-title":"Nat Genet"},{"key":"1978_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27248828","author":"R Li","year":"2022","unstructured":"Li R, Liu M, Yang Z, Li J, Gao Y, Tan R.\u00a0Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules. 2022;27:8828.","journal-title":"Molecules"},{"key":"1978_CR85","volume":"227","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives. Eur J Med Chem. 2022;227:113906.","journal-title":"Eur J Med Chem"},{"key":"1978_CR86","volume":"193","author":"N Sun","year":"2020","unstructured":"Sun N, Ren C, Kong Y, et al. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur J Med Chem. 2020;193:112190.","journal-title":"Eur J Med Chem"},{"key":"1978_CR87","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","volume":"62","author":"X Han","year":"2019","unstructured":"Han X, Wang C, Qin C, et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer. J Med Chem. 2019;62:941\u201364.","journal-title":"J Med Chem"},{"key":"1978_CR88","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","volume":"64","author":"Y Tu","year":"2021","unstructured":"Tu Y, Sun Y, Qiao S, et al. Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma. J Med Chem. 2021;64:10167\u201384.","journal-title":"J Med Chem"},{"key":"1978_CR89","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.celrep.2012.12.007","volume":"3","author":"C Yang","year":"2013","unstructured":"Yang C, Huntoon K, Ksendzovsky A, Zhuang Z, Lonser RR. Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep. 2013;3:52\u20139.","journal-title":"Cell Rep"},{"key":"1978_CR90","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clgc.2019.07.003","volume":"17","author":"E Hasanov","year":"2019","unstructured":"Hasanov E, Tidwell RSS, Fernandez P, et al. Phase II study of carfilzomib in patients with refractory renal cell carcinoma. Clin Genitourin Cancer. 2019;17:451\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"1978_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030601","author":"CB Nguyen","year":"2024","unstructured":"Nguyen CB, Oh E, Bahar P, Vaishampayan UN, Else T, Alva AS.\u00a0Novel Approaches with HIF-2\u03b1 Targeted Therapies in Metastatic Renal Cell Carcinoma. Cancers (Basel). 2024;16:601.","journal-title":"Cancers (Basel)"},{"key":"1978_CR92","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/fon-2023-0679","volume":"20","author":"L Curry","year":"2024","unstructured":"Curry L, Soleimani M. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future Oncol. 2024;20:1251\u201366.","journal-title":"Future Oncol"},{"key":"1978_CR93","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385:2036\u201346.","journal-title":"N Engl J Med"},{"key":"1978_CR94","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2024.08.2338","volume":"35","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Brugarolas J, Ghatalia P, et al. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann Oncol. 2024;35:1148\u201356.","journal-title":"Ann Oncol"},{"key":"1978_CR95","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888\u201398.","journal-title":"Lancet Oncol"},{"key":"1978_CR96","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","volume":"25","author":"O Iliopoulos","year":"2024","unstructured":"Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024;25:1325\u201336.","journal-title":"Lancet Oncol"},{"key":"1978_CR97","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000539434","volume":"10","author":"F Jamshidi","year":"2024","unstructured":"Jamshidi F, Lozano L, Tucker B, et al. Belzutifan in individuals with von Hippel-Lindau retinal hemangioblastomas: institutional experience and review of the literature. Ocul Oncol Pathol. 2024;10:154\u201361.","journal-title":"Ocul Oncol Pathol"},{"key":"1978_CR98","volume":"11","author":"JES Bohonowych","year":"2011","unstructured":"Bohonowych JES, Peng S, Gopal U, et al. Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation. BMC Cancer. 2011;11:520.","journal-title":"BMC Cancer"},{"key":"1978_CR99","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.21873\/anticanres.17154","volume":"44","author":"R Teranishi","year":"2024","unstructured":"Teranishi R, Takahashi T, Kurokawa Y, et al. Pimitespib, a novel heat shock protein 90 inhibitor, is effective in treating renal cell carcinoma by anti-angiogenetic signaling. Anticancer Res. 2024;44:3343\u20138.","journal-title":"Anticancer Res"},{"key":"1978_CR100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.hoc.2023.05.022","volume":"37","author":"RM Saliby","year":"2023","unstructured":"Saliby RM, Saad E, Labaki C, et al. Novel targeted therapies for renal cell carcinoma: building on the successes of vascular endothelial growth factor and mTOR inhibition. Hematol Oncol Clin North Am. 2023;37:1015\u201326.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1978_CR101","doi-asserted-by":"crossref","first-page":"10062","DOI":"10.1038\/s41598-019-46448-6","volume":"9","author":"AM Cuesta","year":"2019","unstructured":"Cuesta AM, Albi\u00f1ana V, Gallardo-Vara E, et al. The \u03b22-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Sci Rep. 2019;9:10062.","journal-title":"Sci Rep"},{"key":"1978_CR102","doi-asserted-by":"crossref","unstructured":"Dell\u2019Atti L, Bianchi N, Aguiari G. New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future. Cancers (Basel). 2022;14:3616.","DOI":"10.3390\/cancers14153616"},{"key":"1978_CR103","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jgg.2021.05.016","volume":"48","author":"M Shulman","year":"2021","unstructured":"Shulman M, Shi R, Zhang Q. Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. J Genet Genomics. 2021;48:552\u20139.","journal-title":"J Genet Genomics"},{"key":"1978_CR104","first-page":"1725","volume":"17","author":"HM Sadique","year":"2026","unstructured":"Sadique HM, Liming Z, Joshi RA, et al. Epigenetic therapy Meets targeted protein degradation: HDAC-PROTACs in cancer treatment. Future Med Chem. 2026;17:1725\u201337.","journal-title":"Future Med Chem"},{"key":"1978_CR105","volume":"255","author":"Y Fan","year":"2025","unstructured":"Fan Y, Liu Y, Wang L, et al. Precision targeting of ALK-positive lung cancer: engineering HFN@MS4078 nanocages for optimized PROTAC delivery. Colloids Surf B Biointerfaces. 2025;255:114974.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1978_CR106","volume":"205","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ming A, Wang J, Chen W, Fang Z. PROTACs targeting androgen receptor signaling: potential therapeutic agents for castration-resistant prostate cancer. Pharmacol Res. 2024;205:107234.","journal-title":"Pharmacol Res"},{"key":"1978_CR107","volume":"140","author":"H Gao","year":"2023","unstructured":"Gao H, Zhang J, Zhao L, Guo Y. Synthesis and clinical application of small-molecule inhibitors and PROTACs of anaplastic lymphoma kinase. Bioorg Chem. 2023;140:106807.","journal-title":"Bioorg Chem"},{"key":"1978_CR108","doi-asserted-by":"crossref","first-page":"788667","DOI":"10.3389\/fphar.2021.788667","volume":"12","author":"X Yan","year":"2021","unstructured":"Yan X, Tian R, Sun J, et al. Sorafenib-Induced autophagy promotes Glycolysis by upregulating the p62\/HDAC6\/HSP90 axis in hepatocellular carcinoma cells. Front Pharmacol. 2021;12:788667.","journal-title":"Front Pharmacol"},{"key":"1978_CR109","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1158\/2767-9764.CRC-21-0084","volume":"2","author":"N Bora-Singhal","year":"2022","unstructured":"Bora-Singhal N, Saha B, Mohankumar D, Padmanabhan J, Coppola D, Chellappan S. A novel PHD2\/VHL-mediated regulation of YAP1 contributes to VEGF expression and angiogenesis. Cancer Res Commun. 2022;2:624\u201338.","journal-title":"Cancer Res Commun"},{"key":"1978_CR110","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10637-019-00821-4","volume":"38","author":"J Chen","year":"2020","unstructured":"Chen J, Luo B, Wen S, Pi R. Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. Invest New Drugs. 2020;38:755\u201364.","journal-title":"Invest New Drugs"},{"key":"1978_CR111","first-page":"175883592513178","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Lazris D, Wong R, Tykodi SS. Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol. 2025;17:17588359251317846.","journal-title":"Ther Adv Med Oncol"},{"key":"1978_CR112","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","volume":"30","author":"J Fallah","year":"2024","unstructured":"Fallah J, Heiss BL, Joeng H, et al. FDA approval summary: belzutifan for patients with advanced renal cell carcinoma. Clin Cancer Res. 2024;30:5003\u20138.","journal-title":"Clin Cancer Res"},{"key":"1978_CR113","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.3390\/curroncol29080429","volume":"29","author":"LM Cardenas","year":"2022","unstructured":"Cardenas LM, Deluce JE, Khan S, et al. Next wave of targets in the treatment of advanced renal cell carcinoma. Curr Oncol. 2022;29:5426\u201341.","journal-title":"Curr Oncol"},{"key":"1978_CR114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","volume":"26","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Merchan JR, Figlin R, et al. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol. 2025;26:64\u201373.","journal-title":"Lancet Oncol"},{"key":"1978_CR115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/fon-2022-0802","volume":"19","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Schmidinger M, Eto M, et al. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy. Future Oncol. 2023;19:113\u201321.","journal-title":"Future Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01978-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01978-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01978-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:29:59Z","timestamp":1767677399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01978-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1978"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01978-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflicts of Interest"}}],"article-number":"90"}}